



## **Xilio Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference**

April 7, 2022

WALTHAM, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that Marty Huber, M.D., president of research and development and chief medical officer, will present at the 21<sup>st</sup> Annual Needham Virtual Healthcare Conference on Thursday, April 13, 2022, at 8:00 a.m. ET.

A live webcast will be available in the Investors and Media section of the Xilio Therapeutics' website at <https://ir.xiliotx.com>. A replay of the webcast will be archived on Xilio Therapeutics' website for 30 days following the presentation.

### **About Xilio Therapeutics**

Xilio Therapeutics is a clinical-stage biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. The company is using its proprietary geographically precise solutions (GPS) platform to rapidly engineer novel molecules, including cytokines and other biologics, that are designed to optimize their therapeutic index. These molecules are designed to localize activity within the tumor microenvironment without systemic effect, resulting in the potential to achieve enhanced anti-tumor activity. Xilio is building a pipeline of wholly owned, tumor-selective, GPS-enabled cytokine and checkpoint inhibitor product candidates, including its clinical-stage programs, XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody, and XTX202, a tumor-selective IL-2, as well as its earlier pipeline, including XTX301, a tumor-selective IL-12, and XTX401, a tumor-selective IL-15. For more information, please visit [www.xiliotx.com](http://www.xiliotx.com).

### **For Investor Inquiries:**

Chelcie Lister, THRUST Strategic Communications  
[chelcie@thrustsc.com](mailto:chelcie@thrustsc.com)

### **For Media Inquiries:**

Dan Budwick  
[dan@1abmedia.com](mailto:dan@1abmedia.com)